De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

LifeMD Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat LifeMD de winst en omzet met respectievelijk 91.1% en 20.1% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 88.3% per jaar.

Belangrijke informatie

91.1%

Groei van de winst

88.3%

Groei van de winst per aandeel

Healthcare Services winstgroei	31.1%
Inkomstengroei	20.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	19 Sep 2024

Recente toekomstige groei-updates

Recent updates

Even With A 29% Surge, Cautious Investors Are Not Rewarding LifeMD, Inc.'s (NASDAQ:LFMD) Performance Completely

Mar 30

LifeMD: Results And Guidance Point To Continued Strength In Weight Management Program

Mar 13

LifeMD's 2024: Striking A Balance Between Rapid Expansion And Sustainability

Jan 22

LifeMD: A GLP-1 Play With A Kicker

Jan 11

Is LifeMD, Inc. (NASDAQ:LFMD) Potentially Undervalued?

Jan 05

Take Care Before Jumping Onto LifeMD, Inc. (NASDAQ:LFMD) Even Though It's 34% Cheaper

Jan 05

Does This Valuation Of LifeMD, Inc. (NASDAQ:LFMD) Imply Investors Are Overpaying?

Dec 03

Investors Still Aren't Entirely Convinced By LifeMD, Inc.'s (NASDAQ:LFMD) Revenues Despite 38% Price Jump

Apr 17

Analysts Are Betting On LifeMD, Inc. (NASDAQ:LFMD) With A Big Upgrade This Week

Nov 17

LifeMD launches at-home screening kits for breast, colon cancers

Sep 14

LifeMD Non-GAAP EPS of -$0.22 beats by $0.01, revenue of $30.5M misses by $1.45M

Aug 11

LifeMD CEO Justin Schreiber - Disrupting Healthcare With Telemedicine

Jan 10

Winst- en omzetgroeiprognoses

NasdaqGM:LFMD - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	294	-2	N/A	N/A	4
12/31/2025	255	-2	13	39	7
12/31/2024	206	-22	7	23	7
6/30/2024	178	-27	7	17	N/A
3/31/2024	164	-26	8	17	N/A
12/31/2023	153	-24	0	9	N/A
9/30/2023	136	-32	-7	1	N/A
6/30/2023	129	-33	-11	-3	N/A
3/31/2023	123	-39	-26	-17	N/A
12/31/2022	119	-49	-36	-23	N/A
9/30/2022	118	-55	-39	-27	N/A
6/30/2022	112	-61	-43	-31	N/A
3/31/2022	104	-64	-42	-32	N/A
12/31/2021	93	-62	-36	-33	N/A
9/30/2021	78	-75	-36	-34	N/A
6/30/2021	64	-85	-32	-31	N/A
3/31/2021	51	-73	-22	-22	N/A
12/31/2020	37	-63	-13	-12	N/A
9/30/2020	28	-32	-6	-5	N/A
6/30/2020	20	-9	-1	-1	N/A
3/31/2020	14	-5	0	0	N/A
12/31/2019	12	-3	0	0	N/A
9/30/2019	11	-3	0	0	N/A
6/30/2019	10	-3	0	0	N/A
3/31/2019	9	-3	-1	0	N/A
12/31/2018	8	-2	-1	-1	N/A
9/30/2018	6	-2	-1	-1	N/A
6/30/2018	6	-2	-1	-1	N/A
3/31/2018	5	-1	N/A	0	N/A
12/31/2017	4	-1	N/A	-1	N/A
9/30/2017	5	-2	N/A	-1	N/A
6/30/2017	3	-1	N/A	-1	N/A
3/31/2017	4	-2	N/A	-1	N/A
12/31/2016	5	-1	N/A	0	N/A
9/30/2016	5	-1	N/A	0	N/A
6/30/2016	4	0	N/A	0	N/A
3/31/2016	3	0	N/A	0	N/A
12/31/2015	1	0	N/A	0	N/A
9/30/2015	1	0	N/A	0	N/A
6/30/2015	1	0	N/A	0	N/A
3/31/2015	1	0	N/A	0	N/A
12/31/2014	1	0	N/A	0	N/A
9/30/2014	1	0	N/A	0	N/A
6/30/2014	1	0	N/A	0	N/A
3/31/2014	1	0	N/A	0	N/A
12/31/2013	1	0	N/A	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat LFMD de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat LFMD de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat LFMD de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van LFMD ( 20.1% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van LFMD ( 20.1% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van LFMD naar verwachting over 3 jaar hoog zal zijn

LifeMD Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

LifeMD, Inc. Provides Financial Guidance for the Third Quarter and Full Year 2024

Consensus estimates of losses per share improve by 38%

Forecast to breakeven in 2025

LifeMD, Inc. Provides Financial Guidance for the Second Quarter of 2024

LifeMD, Inc. Provides Earnings Guidance for the First Quarter of 2024 and Revises Earnings Guidance for the Full Year of 2024

Price target increased by 20% to US$12.20

Recent updates

LifeMD: Are The Commons Too Cheap?

LifeMD: Selling WorkSimpli Could Be A Catalyst

It's Down 27% But LifeMD, Inc. (NASDAQ:LFMD) Could Be Riskier Than It Looks

LifeMD, Inc. Provides Financial Guidance for the Third Quarter and Full Year 2024

LifeMD: High Growth GLP-1 Telehealth Play At A Discount

LifeMD, Inc. to Report Q2, 2024 Results on Aug 07, 2024

LifeMD, Inc. Launches Commercial Health Insurance Acceptance for Its Primary Care Services, Including Weight Management

LifeMD: Pairing GLP-1 Agonists With Virtual Healthcare

LifeMD: Moving Towards Profitability

Consensus estimates of losses per share improve by 38%

Forecast to breakeven in 2025

LifeMD, Inc. Provides Financial Guidance for the Second Quarter of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

LifeMD, Inc., Annual General Meeting, Jun 14, 2024

LifeMD, Inc. Appoints Calum Macrae to Its Board of Directors

LifeMD, Inc. to Report Q1, 2024 Results on May 08, 2024

Is LifeMD (NASDAQ:LFMD) Using Debt Sensibly?

Even With A 29% Surge, Cautious Investors Are Not Rewarding LifeMD, Inc.'s (NASDAQ:LFMD) Performance Completely

LifeMD, Inc. Provides Earnings Guidance for the First Quarter of 2024 and Revises Earnings Guidance for the Full Year of 2024

LifeMD: Results And Guidance Point To Continued Strength In Weight Management Program

Price target increased by 20% to US$12.20

LifeMD, Inc. to Report Q4, 2023 Results on Mar 11, 2024

LifeMD's 2024: Striking A Balance Between Rapid Expansion And Sustainability

LifeMD: A GLP-1 Play With A Kicker

LifeMD, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Is LifeMD, Inc. (NASDAQ:LFMD) Potentially Undervalued?

Take Care Before Jumping Onto LifeMD, Inc. (NASDAQ:LFMD) Even Though It's 34% Cheaper

LifeMD, Inc. announced that it expects to receive $10.000001 million in funding from Jason Pharmaceuticals, Inc.

Does This Valuation Of LifeMD, Inc. (NASDAQ:LFMD) Imply Investors Are Overpaying?

Insufficient new directors

Lifemd, Inc. Announces Resignation of Bertrand Velge from His Position as Member of the Board of Directors

Consensus EPS estimates fall by 12%

LifeMD, Inc. Provides Revenue Guidance for the Fourth Quarter and for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

LifeMD, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Price target increased by 9.7% to US$8.50

Independent Director recently bought US$501k worth of stock

Consensus EPS estimates fall by 57%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

LifeMD, Inc. Provides Earnings Guidance for the Full Year 2023

New major risk - Share price stability

LifeMD, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Price target increased by 46% to US$7.67

LifeMD, Inc. Appoints William J. Febbo to Its Board of Directors

Independent Director recently bought US$170k worth of stock

Chairman & CEO recently bought US$105k worth of stock

Lifemd, Inc. Provides Earnings Guidance for the Second Quarter 2023 and Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

LifeMD, Inc. to Report Q1, 2023 Results on May 12, 2023

Investors Still Aren't Entirely Convinced By LifeMD, Inc.'s (NASDAQ:LFMD) Revenues Despite 38% Price Jump

Consensus EPS estimates upgraded to US$0.46 loss

Full year 2022 earnings: EPS and revenues miss analyst expectations

LifeMD, Inc. Appoints Dr. Joan Larovere to its Board of Directors

LifeMD, Inc. Appoints Jessica Friedeman as Chief Marketing Officer

No longer forecast to breakeven

Analysts Are Betting On LifeMD, Inc. (NASDAQ:LFMD) With A Big Upgrade This Week

Price target decreased to US$8.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

LifeMD, Inc. to Report Q3, 2022 Results on Nov 10, 2022

LifeMD, Inc. Appoints Bobby Jindal to the Board of Directors

LifeMD, Inc. Expands Primary Care Platform’s Diagnostic Capabilities with New At-Home Screening Kits For Early Warning Signs Of Cancer

LifeMD launches at-home screening kits for breast, colon cancers

Consensus EPS estimates fall by 15%

Forecast to breakeven in 2024

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

LifeMD, Inc. Provides Consolidated Earnings Guidance for the Third Quarter 2022 and Full Year 2022

LifeMD Non-GAAP EPS of -$0.22 beats by $0.01, revenue of $30.5M misses by $1.45M

LifeMD, Inc. to Report Q2, 2022 Results on Aug 11, 2022